Proto Labs (PRLB) Projected to Announce Quarterly Earnings on Thursday

Proto Labs (NYSE:PRLB) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Proto Labs to post earnings of $0.5960 per share and revenue of $149.31 million for the quarter. Proto Labs has set its Q3 2026 guidance at 0.560-0.640 EPS. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Proto Labs (NYSE:PRLB) last issued its quarterly earnings data on Friday, July 31st. The industrial products company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.53 by $0.07. The company had revenue of $149.34 million for the quarter, compared to the consensus estimate of $144.53 million. Proto Labs had a net margin of 5.44% and a return on equity of 4.80%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 earnings per share. On average, analysts expect Proto Labs to post $1.46 EPS for the current fiscal year and $1.76 EPS for the next fiscal year.

Proto Labs Price Performance

NYSE PRLB opened at $86.46 on Tuesday. Proto Labs has a 1-year low of $45.10 and a 1-year high of $99.96. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of 69.17 and a beta of 1.38. The business’s fifty day moving average price is $86.47 and its 200-day moving average price is $72.53.

Insiders Place Their Bets

In other Proto Labs news, CFO Daniel Schumacher sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $95.32, for a total transaction of $476,600.00. Following the completion of the sale, the chief financial officer directly owned 35,019 shares of the company’s stock, valued at $3,338,011.08. This trade represents a 12.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 10,000 shares of company stock valued at $902,629. Corporate insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on PRLB shares. Weiss Ratings raised Proto Labs from a “hold (c+)” rating to a “buy (b)” rating in a research report on Friday, October 16th. Needham & Company LLC upped their price target on shares of Proto Labs from $87.00 to $110.00 and gave the company a “buy” rating in a research report on Friday. Benchmark upped their price target on shares of Proto Labs from $70.00 to $91.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Wall Street Zen cut shares of Proto Labs from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Zacks Research downgraded shares of Proto Labs from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.50.

Proto Labs Company Profile

Proto Labs, Inc (NYSE: PRLB), operating as Protolabs, is a digital manufacturing company that provides rapid prototyping and on-demand production services. The company uses automated quoting and manufacturing systems to help engineers and product developers produce custom parts without relying on traditional, lengthy tooling and procurement processes.

Protolabs offers computer numerical control (CNC) machining, injection molding, 3D printing and sheet-metal fabrication. Its services support the development and production of components in a range of materials and are used across industries including automotive, aerospace, medical, electronics and consumer products.

Founded in 1999 by entrepreneur Larry Lukis, the company has expanded its reach beyond its original U.S.